Tempus expands multi-year collaboration with Gilead for oncology research
Go back to Tempus expands multi-year collaboration with Gilead for oncology research| Gilead Sciences (NASDAQ: GILD) | Delayed: 156.19 -1.18 (0.75%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $157.37 | 52 Week High | $108.63 | |||
| Open | $157.32 | 52 Week Low | $71.39 | |||
| Day High | $157.58 | P/E | 86.29 | |||
| Day Low | $155.62 | EPS | $1.81 | |||
| Volume | 7,775,707 | |||||
| StemCells, Inc. (NASDAQ: TEM) | Delayed: 64.72 -6.41 (9.01%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $71.13 | 52 Week High | $0.45 | |||
| Open | $70.89 | 52 Week Low | $0.37 | |||
| Day High | $72.50 | P/E | N/A | |||
| Day Low | $63.79 | EPS | $-0.31 | |||
| Volume | 6,871,181 | |||||



